Kiwe­care strength­ens its glob­al growth path with new CEO and strate­gic col­lab­o­ra­tion with Mayo Clin­ic

Kiwe­care has announced two sig­nif­i­cant devel­op­ments that mark an impor­tant step in the company’s growth strat­e­gy and inter­na­tion­al expan­sion.

New CEO to lead next growth phase

The Board of Direc­tors has appoint­ed Juha Remahl as the new CEO, effec­tive Sep­tem­ber 2025. Remahl has been active­ly involved in Kiwecare’s strate­gic plan­ning, investor engage­ment, and com­mer­cial­iza­tion roadmap. As CEO, he will focus on oper­a­tional exe­cu­tion, strength­en­ing part­ner­ships, and accel­er­at­ing the company’s entry into the U.S. mar­ket.

Strate­gic col­lab­o­ra­tion with Mayo Clin­ic

Kiwe­care has entered a col­lab­o­ra­tion agree­ment with Mayo Clin­ic, one of the world’s lead­ing health­care insti­tu­tions.
This col­lab­o­ra­tion inte­grates Kiwecare’s inno­v­a­tive technology—designed to detect ear­ly signs of infec­tion in peri­toneal dialysis—with Mayo Clinic’s clin­i­cal exper­tise, val­i­da­tion capa­bil­i­ties, and deep under­stand­ing of patient path­ways.

The part­ner­ship sup­ports Kiwecare’s prod­uct devel­op­ment, FDA reg­u­la­to­ry plan­ning, and U.S. clin­i­cal activ­i­ties, and is a sig­nif­i­cant dri­ver for build­ing cred­i­bil­i­ty with glob­al part­ners and investors. Mayo Clinic’s involve­ment under­lines the med­ical and com­mer­cial poten­tial of Kiwecare’s solu­tion in improv­ing qual­i­ty of care for home dial­y­sis patients.

About Kiwe­care

Kiwe­care devel­ops inno­v­a­tive, AI-enabled mon­i­tor­ing solu­tions for peri­toneal dial­y­sis, aim­ing to sup­port ear­li­er detec­tion of com­pli­ca­tions, stream­line work­flows, and improve out­comes for kid­ney patients and care providers glob­al­ly. The com­pa­ny oper­ates in Oulu and Helsin­ki and col­lab­o­rates with lead­ing clin­i­cal and research part­ners.

Con­tact per­son

Juha Remahl
CEO, Kiwe­care
juha.remahl@kiwecare.com

Source (text and image): Smart PD Solu­tions